{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:02:12Z","timestamp":1778896932224,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.soncn.2024.151758","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T23:30:06Z","timestamp":1732318206000},"page":"151758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing\/advanced practice provider perspectives"],"prefix":"10.1016","volume":"41","author":[{"given":"Nicole","family":"McEntee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Manago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChiaChun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2024.151758_bib0001","series-title":"(Brexucabtagene Autoleucel)","year":"2024"},{"key":"10.1016\/j.soncn.2024.151758_bib0002","series-title":"(Tisagenlecleucel)","year":"2024"},{"key":"10.1016\/j.soncn.2024.151758_bib0003","series-title":"(Lisocabtagene Maraleucel)","year":"2024"},{"key":"10.1016\/j.soncn.2024.151758_bib0004","series-title":"(Axicabtagene Ciloleucel)","year":"2024"},{"key":"10.1016\/j.soncn.2024.151758_bib0005","series-title":"(Lisocabtagene Maraleucel) [Summary of Product Characteristics]","year":"2024"},{"issue":"4","key":"10.1016\/j.soncn.2024.151758_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.soncn.2024.151758_bib0007","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"10254","key":"10.1016\/j.soncn.2024.151758_bib0008","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.soncn.2024.151758_bib0009","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10402","key":"10.1016\/j.soncn.2024.151758_bib0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.soncn.2024.151758_bib0011","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.soncn.2024.151758_bib0012","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2024.151758_bib0013","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","author":"Linhares","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.soncn.2024.151758_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.soncn.2024.151758_bib0015","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","article-title":"Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial","volume":"5","author":"Abramson","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.soncn.2024.151758_bib0016","first-page":"487","article-title":"Preparing the patient for bone marrow transplantation: nursing care issues","volume":"63","author":"Holmes","year":"1990","journal-title":"Yale J Biol Med"},{"issue":"4","key":"10.1016\/j.soncn.2024.151758_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/104345429701400406","article-title":"Bone marrow transplant today\u2014home tomorrow: ambulatory care issues in pediatric marrow transplantation","volume":"14","author":"Fidler","year":"1997","journal-title":"J Pediatr Oncol Nurs"},{"issue":"3","key":"10.1016\/j.soncn.2024.151758_bib0018","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1523-5394.2000.83005.x","article-title":"Caregiver responses and needs. An ambulatory bone marrow transplant model","volume":"8","author":"Grimm","year":"2000","journal-title":"Cancer Pract"},{"key":"10.1016\/j.soncn.2024.151758_bib0019","doi-asserted-by":"crossref","first-page":"03051","DOI":"10.7189\/jogh.12.03051","article-title":"\u201cSee one, do one, teach one\u201d: balancing patient care and surgical training in an emergency trauma department","volume":"12","author":"Ayub","year":"2022","journal-title":"J Glob Health"},{"issue":"4","key":"10.1016\/j.soncn.2024.151758_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151178","article-title":"Tisagenlecleucel therapy: nursing considerations for the outpatient setting","volume":"37","author":"Cunningham","year":"2021","journal-title":"Semin Oncol Nurs"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124002420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124002420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:49:18Z","timestamp":1742294958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208124002420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0749208124002420"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151758","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of a lisocabtagene maraleucel chimeric antigen receptor T-cell therapy outpatient monitoring program: Multicenter nursing\/advanced practice provider perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151758"}}